13
Nov 2026
14 million sleep records expose the social divide in sleep
More favorable social conditions are associated with steadier, longer sleep, according to long-term Fitbit data from the All of Us Research Program.

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
13
Nov 2026
More favorable social conditions are associated with steadier, longer sleep, according to long-term Fitbit data from the All of Us Research Program.
13
Nov 2026
A continuous, personalized mobile health (mHealth) coaching programme can significantly reduce gestational diabetes incidence among high-risk pregnant women, independent of changes to maternal weight - according to an international study published today in the Lancet Digital Health.
13
Nov 2026
Machine learning models were able to predict mortality in hospital and in the six months after a type of heart attack, according to results presented today at ESC Digital & AI Summit 2026.
13
Nov 2026
A validated mortality score outperformed the current six-status system, potentially reshaping US donor heart allocation and prioritizing sicker patients.